Haemonetics (HAE) Reiterated at Market Outperform by Citizens on 3Q26 Beats

Citizens analyst David Turkaly reiterated a Market Outperform rating and $100.00 price target on Haemonetics (NYSE: HAE).

The analyst commented, "Haemonetics' F3Q26 included ~2% and ~5% beats on the top and bottom lines, respectively, as outperformance in its Plasma and Blood Center segments offset a mixed quarter in Hospital. While BMT sales were strong (~8% y/y growth), IVT revenue declined ~11% y/y during the quarter due primarily to two issues: 1) ongoing PFA pressure continuing to impact the company's esophageal cooling offerings; and 2) OEM-related headwinds in sensorguided guidewires. That said, we are encouraged by HAE's ongoing momentum in Plasma, which continues to benefit from sustained worldwide demand, and long-term portfolio rationalization efforts continued to illustrate improvements on the cash conversion front (FCF guidance raised by $20 mln at the midpoint and FCF conversion expected to be >80% for the fiscal year). Additionally, management disclosed that it had repurchased ~$25 mln of stock since the quarter's end."

For an analyst ratings summary and ratings history on Haemonetics click here. For more ratings news on Haemonetics click here.

Shares of Haemonetics closed at $65.02 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Aurora Spine settles patent dispute, secures $600K insider loan